SecBot SecBot

ARDX drug pipeline

ARDELYX, INC. · 1 rated drug
$3.18
+3.6% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±10.6%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (IBS-C and hyperphosphatemia); Phase 3 for CIC
Time to marketAlready on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.

tenapanor Updated Nov 5

What to watch

Tenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.

Bull case
  • IBSRELA revenue grew 23% YoY to $96.3M in Q3 2026, with full-year guidance of $350-370M, showing strong commercial execution in a $4.5B+ IBS-C market
  • Analyst consensus is heavily bullish: 16 of 17 analysts rate Buy or Strong Buy, with a mean price target of $12.80 (289% upside from $3.29)
  • New USPTO patent covering commercial formulations extends IP protection to December 2041, providing long-term exclusivity
Bear case
  • Revenue growth is decelerating: from 58% YoY in Q1 2026 to 33% in Q2 to 23% in Q3, and XPHOZAH growth slowed to just 7% in Q3
  • Multiple insiders sold shares on August 21, 2026 at ~$3.86, including the CEO (Michael Raab sold ~$168K), CFO, and other officers, which may signal limited near-term upside conviction
  • Several prominent hedge funds exited or severely trimmed positions in Q2 2026: Point72 exited entirely, Citadel trimmed 70%, Marshall Wace cut 96.5%, and D.E. Shaw cut 95.8%

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Oct 17, 2023tenapanorApproval+12.7%+8.9%
Sep 12, 2019tenapanorApproval−8.4%−15.9%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
tenapanorStudy to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsPhase 3Completed180Aug 20, 2026
tenapanor4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsPhase 2Completed72Jul 7, 2026